MARATTO

article

Designing a Swahili-Speaking Medical Chatbot for Oncology, Dermatology, and Otorhinolaryngology Care in Low-Resource Settings

Abstract

Access to specialized medical care in fields such as otorhinolaryngology, dermatology, and oncology remains critically limited in low-resource settings, particularly among Swahili-speaking populations in East Africa. This paper presents Lueji, a Swahili-speaking medical chatbot designed to assist in providing accessible health information in these domains. A major challenge in building such systems lies in the scarcity of domain-specific Swahili-language medical corpora. To address this, we constructed a Swahili dataset by automatically translating the Huatuo-26M Chinese medical corpus using the GPT-4o-mini model, followed by dataset cleaning, normalization, and human validation. The translated dataset was used to fine-tune the UlizaLlama model, resulting in a specialized chatbot capable of generating medically relevant responses in Swahili. Evaluation using BLEU, ROUGE, and GLEU metrics demonstrated significant performance gains over a baseline model, with Lueji achieving BLEU-1 of 22.17, ROUGE-1 of 31.68, and GLEU of 10.77. These results highlight the effectiveness of combining automatic translation with supervised fine-tuning for low-resource language adaptation. Future work will focus on expanding the dataset, incorporating real-time retrieval-augmented generation (RAG), and conducting field testing with healthcare professionals and patients.

Research topics

  • AI in Service Interactions
  • Vaccine Coverage and Hesitancy

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1109/ictas64866.2025.11155337

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.